Latest Leadership Changes News

Corporate Travel Management (ASX:CTD) has extended its exclusive contract with the UK Ministry of Defence to provide accommodation services for the Afghan Resettlement Programme, with expected transaction values reaching £28 million in the first six months.

Metallium Limited has appointed key board members and executives to strengthen governance and operational capacity as it advances its Flash Joule Heating technology towards commercialisation in the US.

Integral Diagnostics (ASX: IDX) posted strong preliminary FY26 results with revenue nearing $790 million and operating EBITDA up 30%, while announcing Jenny Martin as incoming CFO amid leadership transitions.

Percheron Therapeutics announces Dr Michael Baker as incoming CEO, replacing Dr James Garner who steps down after three years. Baker’s appointment aligns executive incentives with shareholder value as the company prepares for a pivotal HMBD-002 clinical trial.

Coppermoly Limited's Managing Director and CEO Dickson Leah has resigned for personal reasons but will oversee a handover as the board searches for a successor. The company continues to focus on its expanding copper, gold, and critical minerals portfolio across Queensland and Western Australia.

EVE Health Group has progressed its Libbo pilot clinical study for erectile dysfunction with dosing set for Q4 2026 and achieved a major solubility breakthrough for apixaban, while appointing Ben Rohr as CEO to drive commercial growth.

Integral Diagnostics has installed Jason Martinez as its new CEO, marking a leadership change as the company prepares to present its FY26 results. Martinez brings over 20 years of diagnostic imaging experience and aims to drive growth and innovation following the retirement of long-serving CEO Ian Kadish.

SciDev Ltd has landed its first contracts in the data centre sector, targeting water recycling and treatment services for two major Australian hyperscale operators. The deals are expected to generate around $0.5 million in revenue in the first half of FY27, marking a strategic step into a high-growth market.

WasteCo appoints Brian Cohalan as CEO effective August 31, replacing interim Roger Gower, alongside new regional managers and a COO resignation, signaling a strategic leadership reset.

Vitrafy Life Sciences reported an 80% revenue surge and halved its net loss, buoyed by US military validation and major blood network partnerships. A $32 million capital raise fuels its US commercial expansion and manufacturing scale-up.

EROAD has appointed David Leach as CEO, effective October 2026, aiming to leverage his SaaS scaling expertise to accelerate growth and develop an AI-native platform.

Micro-X has named Brian Gonzales as its new CEO, initiating a strategic reset focused on medical CT technology. The company also secured $8 million in convertible note commitments to fund development and extend its financial runway through FY27.